Understanding why patients stop a medication that works — and then rapidly regain what they lost — is one of the most pressing questions in modern obesity medicine. GLP-1 receptor agonists have reshaped how clinicians think about weight regulation, yet real-world adherence tells a sobering story that aggregate trial data rarely capture. This qualitative investigation into lived patient experience fills that gap in ways that biomarkers and scale readings cannot.
Published in JAMA Network Open, the study drew on semistructured video interviews with 30 adults across 15 U.S. states, conducted in mid-to-late 2025. Participants ranged in age with a mean of 54 years, and most were actively taking a GLP-1 receptor agonist at the time of interview. Through inductive thematic analysis, researchers identified eight distinct themes organized under two overarching domains. The first domain centered on patient-reported benefits and trade-offs, with the most prominently cited benefit being a reduction in what participants described as "food noise" — the persistent, intrusive mental preoccupation with eating and appetite that many had not previously recognized as pathological. Seven participants had discontinued treatment entirely, providing a counterpoint perspective on both the experience of stopping and the consequences of doing so.
This study arrives at a moment when GLP-1 discontinuation rates in real-world settings are estimated to exceed 50% within the first year, a figure that stands in stark contrast to the efficacy demonstrated in controlled trials. Qualitative evidence of this kind is methodologically underused in obesity research, yet it captures the psychological architecture of medication adherence that randomized trials are structurally blind to. The concept of "food noise" suppression, if consistently validated, may reframe obesity as involving a neurological burden rather than purely a metabolic one — with implications for how long-term treatment necessity is communicated to patients. Key limitations include the small sample of 30, recruitment through self-selection channels, and the absence of demographic diversity detail in the excerpt. This is best read as hypothesis-generating groundwork rather than definitive evidence, but its publication in a top-tier journal signals growing institutional recognition that patient phenomenology must inform GLP-1 prescribing frameworks.